Author: Aplagon

Aplagon Announces EUR 5 Million Financing to Broaden Phase 2 Trials of its APAC Therapy in Thrombo-Inflammatory Diseases

June 16, 2026
Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia

March 12, 2026

Aplagon Announces EUR 5 Million Financing to Broaden Phase 2 Trials of its APAC Therapy in Thrombo-Inflammatory Diseases